Effect of cilostazol on experimental diabetic neuropathy in the rat

M. Kihara, J. D. Schmelzer, Phillip Anson Low

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Two proposed mechanisms of diabetic neuropathy are microvascular ischaemia and a reduction in Na,K-ATPase activity. We evaluated the effect of cilostazol, a drug that is both a potent phosphodiesterase inhibitor that normalizes nerve Na,K-ATPase and a vasodilator, on nerve blood flow (NBF) to determine whether it would improve experimental diabetic neuropathy. We examined whether epineurally applied cilostazol acted as a vasodilator on the peripheral nerve of normal and diabetic rats, and whether feeding the rats a cilostazol-supplemented diet could improve diabetic neuropathy. Cilostazol increased nerve blood flow (NBF) in a dose-dependent fashion with an EC50 of 10-5.74 mol/l. Cilostazol also normalized NBF in experimental diabetic neuropathy with a 10-4 mol/l local application on the sciatic nerve. In diabetic neuropathy, a cilostazol-supplemented diet improved both NBF and nerve conduction in a dose- and time-dependent fashion. Potential mechanisms of action of cilostazol on the nerve include its effect on NBF, Na, K-ATPase, and restoration of the thromboxane:prostacyclin ratio. Cilostazol may have potential in the treatment of diabetic neuropathy.

Original languageEnglish (US)
Pages (from-to)914-918
Number of pages5
JournalDiabetologia
Volume38
Issue number8
DOIs
StatePublished - 1995

Fingerprint

Diabetic Neuropathies
Vasodilator Agents
Diet
Phosphodiesterase Inhibitors
cilostazol
Thromboxanes
Neural Conduction
Sciatic Nerve
Epoprostenol
Peripheral Nerves
Action Potentials
Ischemia
Pharmaceutical Preparations

Keywords

  • Cilostazol
  • Diabetic neuropathy
  • Nerve blood flow
  • Sciatic nerve
  • Vasodilator

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Effect of cilostazol on experimental diabetic neuropathy in the rat. / Kihara, M.; Schmelzer, J. D.; Low, Phillip Anson.

In: Diabetologia, Vol. 38, No. 8, 1995, p. 914-918.

Research output: Contribution to journalArticle

Kihara, M. ; Schmelzer, J. D. ; Low, Phillip Anson. / Effect of cilostazol on experimental diabetic neuropathy in the rat. In: Diabetologia. 1995 ; Vol. 38, No. 8. pp. 914-918.
@article{e7ce1e0df447486991bcd467adaa5933,
title = "Effect of cilostazol on experimental diabetic neuropathy in the rat",
abstract = "Two proposed mechanisms of diabetic neuropathy are microvascular ischaemia and a reduction in Na,K-ATPase activity. We evaluated the effect of cilostazol, a drug that is both a potent phosphodiesterase inhibitor that normalizes nerve Na,K-ATPase and a vasodilator, on nerve blood flow (NBF) to determine whether it would improve experimental diabetic neuropathy. We examined whether epineurally applied cilostazol acted as a vasodilator on the peripheral nerve of normal and diabetic rats, and whether feeding the rats a cilostazol-supplemented diet could improve diabetic neuropathy. Cilostazol increased nerve blood flow (NBF) in a dose-dependent fashion with an EC50 of 10-5.74 mol/l. Cilostazol also normalized NBF in experimental diabetic neuropathy with a 10-4 mol/l local application on the sciatic nerve. In diabetic neuropathy, a cilostazol-supplemented diet improved both NBF and nerve conduction in a dose- and time-dependent fashion. Potential mechanisms of action of cilostazol on the nerve include its effect on NBF, Na, K-ATPase, and restoration of the thromboxane:prostacyclin ratio. Cilostazol may have potential in the treatment of diabetic neuropathy.",
keywords = "Cilostazol, Diabetic neuropathy, Nerve blood flow, Sciatic nerve, Vasodilator",
author = "M. Kihara and Schmelzer, {J. D.} and Low, {Phillip Anson}",
year = "1995",
doi = "10.1007/s001250050371",
language = "English (US)",
volume = "38",
pages = "914--918",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Effect of cilostazol on experimental diabetic neuropathy in the rat

AU - Kihara, M.

AU - Schmelzer, J. D.

AU - Low, Phillip Anson

PY - 1995

Y1 - 1995

N2 - Two proposed mechanisms of diabetic neuropathy are microvascular ischaemia and a reduction in Na,K-ATPase activity. We evaluated the effect of cilostazol, a drug that is both a potent phosphodiesterase inhibitor that normalizes nerve Na,K-ATPase and a vasodilator, on nerve blood flow (NBF) to determine whether it would improve experimental diabetic neuropathy. We examined whether epineurally applied cilostazol acted as a vasodilator on the peripheral nerve of normal and diabetic rats, and whether feeding the rats a cilostazol-supplemented diet could improve diabetic neuropathy. Cilostazol increased nerve blood flow (NBF) in a dose-dependent fashion with an EC50 of 10-5.74 mol/l. Cilostazol also normalized NBF in experimental diabetic neuropathy with a 10-4 mol/l local application on the sciatic nerve. In diabetic neuropathy, a cilostazol-supplemented diet improved both NBF and nerve conduction in a dose- and time-dependent fashion. Potential mechanisms of action of cilostazol on the nerve include its effect on NBF, Na, K-ATPase, and restoration of the thromboxane:prostacyclin ratio. Cilostazol may have potential in the treatment of diabetic neuropathy.

AB - Two proposed mechanisms of diabetic neuropathy are microvascular ischaemia and a reduction in Na,K-ATPase activity. We evaluated the effect of cilostazol, a drug that is both a potent phosphodiesterase inhibitor that normalizes nerve Na,K-ATPase and a vasodilator, on nerve blood flow (NBF) to determine whether it would improve experimental diabetic neuropathy. We examined whether epineurally applied cilostazol acted as a vasodilator on the peripheral nerve of normal and diabetic rats, and whether feeding the rats a cilostazol-supplemented diet could improve diabetic neuropathy. Cilostazol increased nerve blood flow (NBF) in a dose-dependent fashion with an EC50 of 10-5.74 mol/l. Cilostazol also normalized NBF in experimental diabetic neuropathy with a 10-4 mol/l local application on the sciatic nerve. In diabetic neuropathy, a cilostazol-supplemented diet improved both NBF and nerve conduction in a dose- and time-dependent fashion. Potential mechanisms of action of cilostazol on the nerve include its effect on NBF, Na, K-ATPase, and restoration of the thromboxane:prostacyclin ratio. Cilostazol may have potential in the treatment of diabetic neuropathy.

KW - Cilostazol

KW - Diabetic neuropathy

KW - Nerve blood flow

KW - Sciatic nerve

KW - Vasodilator

UR - http://www.scopus.com/inward/record.url?scp=0029132315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029132315&partnerID=8YFLogxK

U2 - 10.1007/s001250050371

DO - 10.1007/s001250050371

M3 - Article

C2 - 7589876

AN - SCOPUS:0029132315

VL - 38

SP - 914

EP - 918

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 8

ER -